Ken Griffin
CEROW

Ken Griffin’s CERo Therapeutics Warrants CEROW Stock Holding History

Ken Griffin’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-375,000
Closed -$71K – 14284
2022
Q1 		$71K Hold
375,000
– – ﹤0.01% 12571
2021
Q4 		$162K Buy
+375,000
New +$173K ﹤0.01% 12169

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Ken Griffin's CEROW Position: Q2 2022 in Review

Ken Griffin sold out of CERo Therapeutics Warrants (CEROW) in Q2 2022, closing a stake of 375,000 shares — an estimated $71K sold.

Ken Griffin first reported a position in CEROW in Q4 2021 and held it in 2 quarters. The position peaked at $162K in Q4 2021. 41 funds tracked by Wall St. Rank hold CEROW as of Q2 2022.

  • Ken Griffin reported no remaining CERo Therapeutics Warrants position as of Q2 2022 after selling out during the quarter.
  • Ken Griffin sold 375,000 CERo Therapeutics Warrants shares in Q2 2022, an estimated $71K.
  • Ken Griffin first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 2 quarters.
  • Ken Griffin's CERo Therapeutics Warrants position peaked at $162K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.